Wall Street analyst estimates for Aptorum Group Limited (APM): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-07-03 | $-0.30 | ||
| 2026-04-28 | $-1.30 | ||
| 2026-01-22 | |||
| 2025-10-03 | $-0.62 | ||
| 2025-04-30 | $-2.90 | $-2.70 | -7.4% |
| 2024-12-20 | $-5.00 | $-26.00 | +80.8% |
| 2024-04-30 | $5.10 | $-27.00 | +118.9% |
| 2023-12-22 | $-14.30 | $-26.00 | +45.0% |
Valuation Ratios
| Price / Book | 0.34 |
| EV / EBITDA | -4.28 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | $383450 | $535166 | $911509 | $1.5M | $1.3M | $431378 | 0 | 0 |
| Cost of Revenue | $58903 | $318011 | $794545 | $1.0M | $1.5M | $1.2M | $420396 | $256000 | 0 |
| Gross Profit | -$58903 | $65439 | -$259000 | -$104000 | $81854 | $80065 | $10982 | -$256000 | 0 |
| Research & Development | $2.5M | $3.1M | $6.9M | $11.6M | $10.9M | $9.2M | $5.2M | $1.9M | $352879 |
| Selling, General & Admin | $2.9M | $6.7M | $10.8M | $7.7M | $8.0M | $8.0M | $4.4M | $1.5M | $1.6M |
| Operating Expenses | $5.6M | $10.4M | -$259000 | $20.2M | $19.3M | $17.3M | $10.6M | $3.5M | $1.8M |
| Operating Income | -$5.7M | -$10.3M | -$18.2M | -$19.9M | -$19.2M | -$17.5M | -$10.6M | -$3.8M | -$1.8M |
| EBITDA | -$2.5M | -$10.0M | -$15.1M | $6.5M | -$25.8M | -$10.3M | -$9.5M | -$3.8M | -$1.8M |
| Interest Expense | 0 | $4.5M | $3.7M | $243628 | $93601 | 0 | $121145 | $146924 | $95713 |
| Pre-tax Income | -$2.6M | -$15.1M | -$20.1M | $4.9M | -$27.1M | -$11.5M | -$4.3M | -$4.2M | -$1.4M |
| Income Tax | -$14048 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$2.5M | -$14.8M | -$18.7M | $7.1M | -$25.0M | -$9.8M | -$2.8M | -$4.3M | -$1.4M |
| EPS | $-8.50 | $-53.10 | $-64.00 | $20.30 | $-71.50 | $-27.50 | $-6.20 | $-7.80 | $-1.90 |
| EPS (Diluted) | $-8.50 | $-53.10 | $-64.00 | $20.00 | $-71.50 | $-27.50 | $-6.20 | $-7.80 | $-1.90 |
| Shares Outstanding (Diluted) | $301200 | $279100 | $290100 | $315300 | $350300 | $356900 | $452100 | $545300 | $735178 |
Price
| Price | $8.26 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADIL · ADXN · ARDS · ATHE · ATXI · OXBR · RKTO
Explore sector: Healthcare · Biotechnology
More sections of APM: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks